Abstract:Background: Rilpivirine (RPV) is a potent and selective non-nucleoside reverse transcriptase inhibitor (NNRTI) of the diarylpyrimidine family with unique antiviral activity, low toxicity and high specificity. It is approved by the U.S. FDA (Food and Drug Administration) in 2011 to treat individuals infected with human immunodeficiency virus 1 (HIV-1). Significantly, rilpivirine is 3-fold more potent than etravirine. Once-daily, it is used with a low oral dose (25mg/tablet), decreasing the drug administration a… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.